| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4589b30807b53be5b8d5c09bfad19dc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y208-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-13 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10 |
| filingDate |
2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c71558ad1634ffeb1512c1a768cc4aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d833a551f6423da1aed6fd52a9f14f28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c973198d9d4b5c885ddb47375f981bbb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a30b584f0a9e376ad711984f77deefe1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5df54f882a55d4609f98fd9405db614
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f65ff5cc0d94879416b9887ed9e8d2ea |
| publicationDate |
2021-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021113607-A1 |
| titleOfInvention |
Enzymatic preparation of increased anticoagulant bovine sourced heparin |
| abstract |
A heparin structure with increased anticoagulant activity and method of making the same are disclosed. A heparin sample is provided and treated with a heparan sulfate sulfotransferase in an enzymatic reaction to add sulfuryl groups from a sulfuryl group source to the heparin sample, resulting in a heparin structure having above about 8% more 3-O-sulfo groups relative to wild-type bovine intestinal heparin. The added sulfuryl groups modify the heparin structure and increase the sample's binding to antithrombin III and its anticoagulant activity to be more similar and a viable alternative to porcine intestinal heparin. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, and a ratio of the anti-FXa activity to the anti-FIIa activity of about 0.9 to about 1.1, consistent with U.S. Pharmacopeia (USP) heparin activity specifications. |
| priorityDate |
2017-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |